Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum  

作　　者：DAI SongWei1,2, WANG XiaoMin1,2, LIU LiYun1,2, LIU JiFu3, WU ShanShan3, HUANG LingYun1,2, XIAO XueYuan1,2 & HE DaCheng1,2 1 Key Laboratory of Cell Proliferation and Regulation of Ministry of Education, Beijing Normal University, Beijing 100875, China 2 Universities’ Confederated Institute of Proteomics, Beijing 100875, China 3 Department of Thoracic Surgery, General Hospital of Beijing Unit, PLA, Beijing 100500, China 

出　　处：《Science China(Life Sciences)》2007年第3期305-311,共7页中国科学（生命科学英文版）

基　　金：the Major State Basic Research Program of China (Grant No. 2006CB910100);National Natural Science Foundation of China (Grant No. 30370712);Natural Science Foundation of Beijing (Grant No. 7051002);Sci-ence Technology Committee of Beijing (Grant No.Y0204002040111)

摘　　要：Two hundred and eighteen serum samples from 175 lung cancer patients and 43 healthy individuals were analyzed by using Surface Enhaced Laser Desorption/Ionization Time of Flight Mass Spectrome- try (SELDI-TOF-MS). The data analyzed by both Biomarker Wizard? and Biomarker Patterns? software showed that a protein peak with the molecular weight of 11.6 kDa significantly increased in lung cancer. Meanwhile,the level of this biomarker was progressively increased with the clinical stages of lung cancer. The candidate biomarker was then obtained from tricine one-dimensional sodium dodecyl sul- fate-polyacrylamide gel electrophoresis by matching the molecular weight with peaks on WCX2 chips and was identified as Serum Amyloid A protein (SAA) by MALDI/MS-MS and database searching. It was further validated in the same serum samples by immunoprecipitation with commercial SAA antibody. To confirm the SAA differential expression in lung cancer patients, the same set of serum samples was measured by ELISA assay. The result showed that at the cutoff point 0.446(OD value)on the Receiver Operating Characteristic (ROC) curve, SAA could better discriminate lung cancer from healthy indi- viduals with sensitivity of 84.1% and specificity of 80%. These findings demonstrated that SAA could be characterized as a biomarker related to pathological stages of lung cancer.Two hundred and eighteen serum samples from 175 lung cancer patients and 43 healthy individuals were analyzed by using Surface Enhaced Laser Desorption/Ionization Time of Flight Mass Spectrome- try (SELDI-TOF-MS). The data analyzed by both Biomarker Wizard? and Biomarker Patterns? software showed that a protein peak with the molecular weight of 11.6 kDa significantly increased in lung cancer. Meanwhile,the level of this biomarker was progressively increased with the clinical stages of lung cancer. The candidate biomarker was then obtained from tricine one-dimensional sodium dodecyl sul- fate-polyacrylamide gel electrophoresis by matching the molecular weight with peaks on WCX2 chips and was identified as Serum Amyloid A protein (SAA) by MALDI/MS-MS and database searching. It was further validated in the same serum samples by immunoprecipitation with commercial SAA antibody. To confirm the SAA differential expression in lung cancer patients, the same set of serum samples was measured by ELISA assay. The result showed that at the cutoff point 0.446(OD value)on the Receiver Operating Characteristic (ROC) curve, SAA could better discriminate lung cancer from healthy indi- viduals with sensitivity of 84.1% and specificity of 80%. These findings demonstrated that SAA could be characterized as a biomarker related to pathological stages of lung cancer.

关 键 词：LUNG Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum 

分 类 号：R734.2[医药卫生—肿瘤]